Search Results

In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.

On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

October 26, 2023. Novozymes delivers 5% organic sales growth, an EBIT-margin of 25.5% before special items, and ROIC including goodwill of 16.3% before special items in the first nine months of the 2023 financial year.

Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+.

Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the first half of the 2023 financial year.

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics Evaluation and Research; Bayer cuts 2,000 more employees; Eli Lilly’s Zepbound scores again; and the Galapagos story turns again.

In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.